We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
Read MoreHide Full Article
Ionis Pharmaceuticals (IONS - Free Report) signed an exclusive worldwide deal with small biotech Bicycle Therapeutics (BCYC - Free Report) to develop targeted oligonucleotide therapies, leveraging the latter’s tissue-targeting TfR1 Bicycle technology. The deal will provide Ionis an exclusive license to Bicycle Therapeutics’ innovative transferrin receptor 1-targeting peptides, referred to as Bicycles, to strengthen the targeting capabilities of its LIgand Conjugated Antisense (LICA) medicines.
Bicycles, a targeting technology, binds with high specificity to the transferrin receptor without modifying natural function. Ionis will evaluate Bicycles as vehicles to deliver oligonucleotide therapeutics to specific organ systems.
This year so far, Ionis’ shares have declined 35.7% compared with the industry’s decrease of 8.4%.
Image Source: Zacks Investment Research
For the deal, Bicycle Therapeutics got an upfront payment of $45 million, which included an $11 million equity investment in the company. Bicycle Therapeutics will also be entitled to other development and regulatory milestone payments as well as future royalties if any drug is developed under the program is eventually approved. However, Bicycle retains rights to use transferrin binding Bicycles to deliver all non-oligonucleotide therapeutics.
Ionis’ RNA antisense technology has allowed it to form an impressive set of partnerships with leading drugmakers like Biogen (BIIB - Free Report) , AstraZeneca (AZN - Free Report) , Bayer, Glaxo among other for development/marketing of its drugs. Ionis is also advancing and expanding its wholly-owned pipeline to drive future revenue growth.
Ionis currently carries a Zacks Rank #5 (Strong Sell).
Image: Bigstock
Ionis (IONS) Inks Deal With Bicycle Therapeutics for LICA Drugs
Ionis Pharmaceuticals (IONS - Free Report) signed an exclusive worldwide deal with small biotech Bicycle Therapeutics (BCYC - Free Report) to develop targeted oligonucleotide therapies, leveraging the latter’s tissue-targeting TfR1 Bicycle technology. The deal will provide Ionis an exclusive license to Bicycle Therapeutics’ innovative transferrin receptor 1-targeting peptides, referred to as Bicycles, to strengthen the targeting capabilities of its LIgand Conjugated Antisense (LICA) medicines.
Bicycles, a targeting technology, binds with high specificity to the transferrin receptor without modifying natural function. Ionis will evaluate Bicycles as vehicles to deliver oligonucleotide therapeutics to specific organ systems.
This year so far, Ionis’ shares have declined 35.7% compared with the industry’s decrease of 8.4%.
Image Source: Zacks Investment Research
For the deal, Bicycle Therapeutics got an upfront payment of $45 million, which included an $11 million equity investment in the company. Bicycle Therapeutics will also be entitled to other development and regulatory milestone payments as well as future royalties if any drug is developed under the program is eventually approved. However, Bicycle retains rights to use transferrin binding Bicycles to deliver all non-oligonucleotide therapeutics.
Ionis’ RNA antisense technology has allowed it to form an impressive set of partnerships with leading drugmakers like Biogen (BIIB - Free Report) , AstraZeneca (AZN - Free Report) , Bayer, Glaxo among other for development/marketing of its drugs. Ionis is also advancing and expanding its wholly-owned pipeline to drive future revenue growth.
Ionis currently carries a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.